Chinese Biopharmaceutical Association-USA (CBA) was established in 1995. It is the largest Chinese-American professional association in the USA. The primary purpose of CBA is to serve as a bridge to facilitate comprehensive communications and collaboration in the biopharmaceutical fields between the USA and China, and to provide a good environment for the development and cooperation of biopharmaceutical companies and scientific research institutions.
CBA is headquartered in Maryland and has branches in Boston, Philadelphia, and Canada. It currently has more than 10,000 individual members and over 1,000 corporate members. The members of CBA come from diverse sources, including emerging technology companies in the USA and China, multinational pharmaceutical companies, colleges and universities, scientific research institutions, government regulatory agencies such as the FDA, various research and industrial development support funds, legal and intellectual property firms, and other professional organizations. More than 80% of CBA’s individual members have a doctoral degree. With CBA’s increasing contributions to biopharmaceuticals, more and more members have made significant achievements in scientific research and economic development in both China and the USA. Many senior American scientists, successful entrepreneurs, and bioinvestors have become members of CBA. CBA has a good reputation internationally, with members all over the world, including China, the USA, Europe, Canada, Australia, Singapore and Japan.
Over the past 28 years, CBA has consistently adhered to its mission of promoting communications and collaboration among biopharmaceutical professionals. It is also committed to advancing the life sciences and health industries fostering business cooperation and partnerships between different countries and regions, especially between China and the USA. CBA has become an incubator for talents and entrepreneurs, cultivating an environment for collaborative growth and innovation among biopharmaceutical companies and research institutions. CBA has hosted or co-organized special workshops, seminars, annual meetings, and social activities annually with other organizations. It has become a platform that allows professionals to share knowledge and in-depth learning, lead industry development, build connections, and pursue career development. CBA has grown through the dedication of its members and the continuous support of partners and sponsors, year after year.
CBA is actively promoting the exchange of biopharmaceutical talents and collaborative projects between China and the USA, while also focusing on developing and commercializing innovative pharmaceutical products. The scope includes vaccines, new anti-tumor drugs and antibodies, nucleic acid drugs, human longevity and health, microbial molecular diagnosis, gene therapy, artificial intelligence and precision medicine, modern biopharmaceutical manufacturing, laws, and regulatory regulations, investment funds for various research and industrial development projects. CBA aims to meet the global clinical needs for the treatment of various diseases, striving to serve patients in multiple ways and benefit mankind. Within the fields of innovation and entrepreneurship, many outstanding and hard-working entrepreneurs and investors have emerged from the presidents and members of CBA, achieving remarkable results. At the same time, they have made a positive contribution to scientific and technological exchanges, especially in biopharmaceuticals. In the future, the global biopharmaceutical and healthcare industries will continue to face many challenges and opportunities. CBA is committed to forging ahead, actively preparing to meet these new opportunities and challenges!
Stand builder YOHO EXPO e-Mail info@yoho-expo.net
沒有留言:
張貼留言